| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Abivax S.A.
13D/A
ABVX · 00370M103
|
4.3% |
7/6/2026
Event 7/2/2026
|
||||
| Sofinnova Crossover I SLP | 4.3% | |||||
| Sofinnova Partners SAS | 4.3% | |||||
| Antoine Papiernik | 4.3% | |||||
| Cedric Moreau | 4.3% | |||||
| Kinam Hong | 4.3% | |||||
| Joseph Anderson | 4.3% | |||||
| Jacques Theurillat | 4.3% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Inventiva, S.A.
13G/A
IVA · 46124U107
|
8.6% |
2/17/2026
Event 12/31/2025
|
||||
| Sofinnova Crossover I SLP | 5.6% | |||||
| Sofinnova Crossover II SLP | 3.1% | |||||
| Sofinnova Partners SAS, a French corporation | 8.6% | |||||
| Antoine Papiernik | 8.6% | |||||
| Cedric Moreau | 8.6% | |||||
| Kinam Hong | 8.6% | |||||
| Joseph Anderson | 8.6% | |||||
| Jacques Theurillat | 5.6% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.